“The international probiotic market is growing at a breakneck pace, and the interest in GanedenBC30 is astounding,” said Mike Bush, senior VP at Ganeden Biotech. “Achieving a global footprint for GanedenBC30 has been an ongoing goal for Ganeden Biotech that could only be achieved by a significant investment in international regulatory compliance and patent prosecution, working with international distributors and continuing to publish studies in peer-reviewed journals that support claims for safety and efficacy.”
© FoodBev Media Ltd 2024